Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00102531
Status:
COMPLETED
Last Update Posted:
2017-08-01
First Post:
2005-01-29
Brief Title:
Inhalation SLIT Cisplatin Liposomal for the Treatment of Osteosarcoma Metastatic to the Lung
Sponsor:
Insmed Incorporated
Organization:
Insmed Incorporated
Study Overview
Official Title:
Phase IbIIa Study of SLIT Cisplatin by Inhalation in the Treatment of Patients Wtih RelapsedProgressive Osteosarcoma Metastatic to the Lung
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase IbIIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal SLIT cisplatin administered every 14 days to patients with relapsedprogressive osteosarcoma metastatic to the lung
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None